Swiss pharmaceutica giant Roche is expanding in the field of digital pathology with an agreement to acquire United States firm PathAI.
+Get the most important news from Switzerland in your inbox
With this acquisition, Roche aims to expand its position in AI-based diagnostic solutions.
The purchase price is $750 million plus potential milestone payments of up to $300 million, the company announced.
+ Why Roche’s supercomputer is a big deal
The combination of PathAI’s AI-powered Image Management System (IMS) with Roche’s diagnostic expertise is expected to increase the efficiency of laboratories, accelerate the development of new clinical therapies and enable the discovery of new biomarkers and new diagnostic tools.
Roche expects this to be a further step towards personalised medicine.
Roche and PathAI already entered into a collaboration in 2021, which was intensified in 2024. Roche expects the acquisition of PathAI to be completed in the second half of the current year, subject to fulfilment of the usual regulatory and competition law conditions.
Once the transaction closes, Roche intends to integrate PathAI into its own diagnostics division.
More
More
Science podcast: the AI revolution in drug development
Adapted from German by AI/mga
We select the most relevant news for an international audience and use automatic translation tools to translate them into English. A journalist then reviews the translation for clarity and accuracy before publication.
Providing you with automatically translated news gives us the time to write more in-depth articles. The news stories we select have been written and carefully fact-checked by an external editorial team from news agencies such as Bloomberg or Keystone.
If you have any questions about how we work, write to us at english@swissinfo.ch.
